Injectable Drug Delivery Market Forecast: USD 1,034.78 Billion By 2030 Marketsandmarketstm

(MENAFN- GlobeNewsWire - Nasdaq) Delray Beach, FL, Sept. 07, 2026 (GLOBE NEWSWIRE) -- MarketsandMarketsTM projects the global injectable drug delivery market will grow from USD 690.23 billion in 2025 to USD 1,034.78 billion by 2030, at a CAGR of 8.4% during the forecast period. Market growth is fueled by the rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders, increasing demand for biologics, advancements in injectable formulations, and the growing adoption of patient-friendly drug delivery devices including prefilled syringes, autoinjectors, pen injectors, wearable injectors, and needle-free systems.

Get PDF Brochure - Market Data & Segmentation:

Key Market Highlights

• Market size, 2025: USD 690.23 billion
• Market forecast, 2030: USD 1,034.78 billion
• Growth rate: CAGR of 8.4% (2025–2030)
• Largest product segment: Formulations
• Largest therapeutic application segment: Autoimmune diseases
• Largest end-user segment: Hospitals & clinics
• Largest regional market: North America
• Fastest growth opportunity: Novel drug delivery systems, self-injection devices, and partnerships & collaborations
• Key players: Johnson & Johnson Services, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Cardinal Health (US), BD (US), B. Braun SE (Germany), Baxter (US), and Terumo Corporation (Japan)

Why This Market Matters

The injectable drug delivery market is expanding as the global burden of chronic diseases continues to rise and demand for biologics increases. Injectable administration provides high bioavailability, rapid onset of action, and precise drug delivery, making it an important route for the treatment of cancer, diabetes, cardiovascular diseases, autoimmune disorders, and other chronic and infectious diseases. The growing adoption of self-administration technologies is also improving patient autonomy and compliance, while increasing healthcare access in emerging markets such as India, Brazil, and China is supporting market expansion.

Market Overview

The injectable drug delivery market is witnessing sustained growth as pharmaceutical and medical device companies develop advanced delivery technologies to address the increasing demand for biologics and chronic disease therapies. The market includes injectable drug delivery devices and formulations, with innovations ranging from nanoparticles, microparticles, and liposomes to prefilled syringes, cartridges, autoinjectors, pen injectors, wearable injectors, and needle-free systems. The increasing focus on personalized medicine, combination therapies, home-based care, and patient-friendly administration is further supporting market development.

Analyst Perspective

The injectable drug delivery industry is moving toward more convenient, connected, and patient-centric delivery solutions. Smart injectors with connectivity and adherence monitoring, large-volume subcutaneous delivery systems, microneedles, needle-free injectors, and wearable delivery technologies are creating new opportunities for manufacturers. Partnerships between pharmaceutical companies and device developers are also accelerating the development of biologics-compatible drug delivery platforms. At the same time, companies are increasingly exploring sustainable and reusable injection systems to address environmental requirements.

Speak to Our Analyst - Get Custom Insights:

Segment Analysis

By product, the formulations segment accounted for the largest share of the injectable drug delivery market in 2024. The dominance of this segment is driven by the increasing use of biologics and biosimilars, which require parenteral administration for efficacy and stability. Rising incidence of chronic and infectious diseases, particularly oncology, diabetes, autoimmune disorders, and hormonal conditions, is further increasing demand for high-potency and fast-acting injectable formulations. The growing use of monoclonal antibodies, insulin analogs, and long-acting injectables is also supporting segment growth.

By therapeutic application, the autoimmune diseases segment accounted for the largest market share in 2024. The chronic nature of autoimmune disorders such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease and the widespread use of biologics requiring parenteral administration are key factors supporting segment growth. Increasing adoption of autoinjectors and pen injectors is enabling more convenient at-home administration, while regulatory approvals for biosimilars and novel monoclonal antibodies are expanding treatment options.

By end user, the hospitals & clinics segment accounted for the largest share of the market in 2024. This dominance is attributed to the high volume of inpatient and outpatient procedures requiring rapid and controlled drug administration. Hospitals and clinics provide the infrastructure required for complex therapies such as chemotherapy, biologics, and critical care drugs. Increasing adoption of smart injectors, closed-system drug transfer devices, prefilled syringes, and long-acting injectables is further supporting the segment.

Regional Analysis

North America dominated the injectable drug delivery market in 2024. The region's leading position is supported by a high burden of chronic diseases such as diabetes, cancer, and rheumatoid arthritis, well-established healthcare infrastructure, early adoption of biologics, and strong reimbursement policies. The US also has a robust regulatory framework and a high concentration of pharmaceutical and biotechnology companies investing in advanced injectable therapies.

The growing demand for self-administration devices and home-based care is further supporting regional market growth. Autoinjectors, wearable injectors, and needle-free systems are gaining adoption due to their user-friendly designs and reduced dependence on clinical settings. Connected injectable systems, biosimilars, large-volume subcutaneous delivery devices, and strategic collaborations between pharmaceutical and device manufacturers are also shaping the North American market.

Key Industry Trends

• Increasing adoption of wearable injectors and autoinjectors
• Growing use of needle-free injection technologies
• Rising demand for home-based and self-administered therapies
• Increasing development of smart injectors with connectivity capabilities
• Growing adoption of large-volume subcutaneous delivery systems
• Increasing use of biologics and biosimilars
• Advancements in microneedles, nanoparticles, microparticles, and liposomes
• Growing focus on sustainable and reusable injection systems
• Increasing pharmaceutical-device partnerships for biologics-compatible delivery platforms

Competitive Landscape

The competitive landscape of the injectable drug delivery market is led by established pharmaceutical, biotechnology, medical device, and healthcare companies including Johnson & Johnson Services, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Cardinal Health (US), BD (US), B. Braun SE (Germany), Baxter (US), and Terumo Corporation (Japan).

The injectable drug delivery market is categorized into devices and formulations. The top five companies in the injectable drug delivery devices segment are Cardinal Health, BD, Baxter, B. Braun SE, and Terumo Corporation. Cardinal Health is focusing on data analytics, artificial intelligence, predictive modeling, innovation, and strategic partnerships. BD maintains a strong presence through its extensive portfolio of medical devices, diagnostics, and bioscience solutions, as well as strategic partnerships. Baxter is strengthening its position through strategic alliances and acquisitions, while B. Braun SE is expanding its manufacturing capabilities and pursuing strategic acquisitions. Terumo Corporation is benefiting from growth in markets such as India and China and investments in ePRISM technology.

The top five companies in the injectable drug delivery formulations market are Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., and Novartis AG. These companies are strengthening their market positions through portfolio expansion, strategic partnerships and acquisitions, product and technology innovation, and continued investment in research and development.

Related Reports
US Injectable Drug Delivery Market
UK Injectable Drug Delivery Market

CONTACT: About MarketsandMarketsTM: MarketsandMarketsTM has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarketsTM is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStoreTM, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit TM.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarketsTM INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email:... Visit Our Website:

MENAFN07092026004107003653ID1111631596